🕒 Last update: loading…21/11/2026

Stock Coloplast A/S COLO-B.CO

Coloplast A/S — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 36.60%

Price change 2019 → 2020: 12.49%

Price change 2020 → 2021: 23.82%

Price change 2021 → 2022: -29.45%

Price change 2022 → 2023: -4.93%

Price change 2023 → 2024: 1.84%

Price change 2024 → 2025: -30.50%

Price change 2025 → 2026: -11.58%

Price change 2026 (year to date): -9.94%

Financial growth

Revenue CAGR (8 years): 7.83%

Earnings CAGR (8 years): -0.80%

Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.

Debt

Debt-to-equity ratio: 1.40

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 22.89

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 0.33% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Coloplast A/S24.11.40+7.2 %🔒
Charles River Laboratories International, Inc.34.10.97+8.8 %–
Ipsen S.A.26.90.20+7.9 %–
Sonova Holding AG31.40.66+5.6 %–
BioNTech SE–0.01+60.8 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Coloplast A/S over the latest fiscal years.

Revenue
4.3 bn USD
fiscal year 2026
Net income
453 m USD
fiscal year 2026
Net margin
10.6 %
fiscal year 2026
Average annual growth
+8.3 %
Revenue growth over 5 years
Average annual growth
+7.0 %
Revenue growth over 10 years
Market cap
16.9 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20212.9 bn711 m24.8 %n/a
20223.3 bn694 m20.8 %+16.2 %
20233.6 bn705 m19.5 %+8.5 %
20244.0 bn745 m18.7 %+10.3 %
20254.1 bn536 m13.0 %+3.1 %
20264.3 bn453 m10.6 %+3.8 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Coloplast A/S over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
solid accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
3.66
safe zone (above 2.99)
Piotroski Score
7 / 9
7 to 9: solid accounts
DCF Value
926.60 DKK
DCF above share price · share price 499.50 DKK, gap +85.5 %
Net Debt / EBITDA
1.82 x
moderate debt
Fiscal year20222023202420252026
Cash and investments633 m911 m788 m947 m511 m
Total Debt18.7 bn19.6 bn22.6 bn22.6 bn21.5 bn
Net Debt18.3 bn18.7 bn21.8 bn21.7 bn21.0 bn
Equity8.3 bn17.3 bn17.9 bn16.1 bn14.3 bn
Total assets35.0 bn48.2 bn48.1 bn48.4 bn46.3 bn
Operating cash flow5.1 bn4.2 bn2.8 bn6.6 bn8.0 bn
Investments (capex)1.1 bn1.2 bn1.2 bn1.4 bn1.6 bn
Free cash-flow4.0 bn3.0 bn1.6 bn5.3 bn6.6 bn
Share buybacks619 m0000
Dividends paid4.0 bn4.2 bn4.7 bn5.0 bn5.2 bn

Amounts in DKK, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)36.62 x
Price / book value7.88 x
Return on Equity (ROE)22.6 %
Return on Invested Capital (ROIC)14.8 %
Net margin10.6 %
Debt / equity1.51 x
Current ratio0.74 x
Interest coverage10.24 x
Free cash-flow yield5.9 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Coloplast A/S compared with its sector on the same exchange and with its main competitors.

Company P/E
24.1

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Coloplast A/S publish: ratings, price targets and earnings forecasts.

Majority rating
hold
21 analysts

Breakdown of ratings

strong buy 0buy 3hold 15sell 2strong sell 1

Price targets: published for companies listed in the United States only.

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
202628.9 bn5.6 bn25.45 (24.25 / 26.69)20.018
202731.0 bn5.8 bn26.26 (24.49 / 28.88)19.318
202833.0 bn6.3 bn28.39 (24.13 / 30.00)17.916

Amounts in DKK, the reporting currency.

Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

PEA and practical information

PEA eligibility
likely
head office in the EU or EEA, listed on a European exchange
Listing exchange
Nasdaq Copenhagen
IPO: 02/01/2000
ISIN code
DK0060448595
Workforce
16,741
full-time employees
Chief executive
Anders Lonning-Skovgaard
Next earnings
09/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Coloplast A/S

What is the Coloplast A/S share price?

Latest recorded price: 508.00 DKK on 13/11/2026, for a market cap of 16.9 bn USD.

What is the revenue of Coloplast A/S?

4.3 bn USD for fiscal year 2026, with net income of 453 m USD (net margin 10.6 %).

When does Coloplast A/S report its next earnings?

The next release is expected on 09/02/2027. EPS expected by analysts: 6.19.

What do analysts say about Coloplast A/S?

Out of 21 analysts: 3 buy or strong buy, 15 hold, 3 sell or strong sell.

What is the P/E ratio of Coloplast A/S?

Trailing 12-month P/E of 24.1.

Is Coloplast A/S stock eligible for the French PEA?

Likely: the company is headquartered in the European Union or the European Economic Area (ISIN DK0060448595) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.

How many employees does Coloplast A/S have?

16,741 full-time employees according to the latest published profile.

Who runs Coloplast A/S?

Anders Lonning-Skovgaard is the company's chief executive.

07

Similar stocks